IGM Biosciences (IGMS)
(Real Time Quote from BATS)
$9.04 USD
-0.20 (-2.17%)
Updated May 29, 2024 12:34 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Brokerage Reports
0 items in cart
IGM Biosciences, Inc. [IGMS]
Reports for Purchase
Showing records 21 - 40 ( 87 total )
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; Quarter of Execution in the Books
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- Roundup for 2023 AACR Meeting
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Imvotamab to Move Into Autoimmunity; 4Q22 Financials; Lowering PT to $22
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Q4/FY22 Financials; ?8444 Study Underway; Imvotamab Pivots to Autoimmunity
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology -AACR 2023 Abstract Roundup For Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Initial IGM-8444 Data Promising; Imvotamab Development Broadens
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Multiple Myeloma Landscape - CD38, BCMA, GPRC5D, and FcRH5 (Version 1.0)
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
ASH Updates: IGM-2664 and IGM-2537 Profiles; Imvotamab Biomarker Insight
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Collaboration Inked With ADC Therapeutics; 3Q22 Financials; Modulating PT to $45
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
Company: IGM Biosciences, Inc.
Industry: Medical - Biomedical and Genetics
1Q22 Financials Reported; Modulating PT to $58; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: BURNS R